FCAG
MRNA icon

First Capital Advisors Group’s Moderna MRNA Stock Holding History

First Capital Advisors Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$18.5K Buy
+152
New +$20.3K 0.01% 439

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Capital Advisors Group's MRNA Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Moderna (MRNA) in Q2 2023: 152 shares worth $18.5K. The stake represents 0.01% of the portfolio and ranks #439 among its holdings.

965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • First Capital Advisors Group held 152 shares of Moderna worth $18.5K as of Q2 2023.
  • Moderna was a new First Capital Advisors Group position in Q2 2023.
  • Moderna made up 0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #439 holding.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.